RxDoctor Payments Data

David Headen, MD

Internal Medicine · Beachwood, OHNPI 1528160348

Payments from drug & device makers

$8,347in general payments, 2019–2025

Across 512 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$936
  • Novo Nordisk$781
  • AbbVie$719
  • AstraZeneca$631
  • Amgen$581
  • Lilly USA, LLC$442
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,28899%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,347 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$80,680
Medicare patients
245
Services billed
1,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide215$221,810
JardianceEmpagliflozin100$105,687
XareltoRivaroxaban86$77,841
TrulicityDulaglutide70$73,804
EliquisApixaban67$60,447
FarxigaDapagliflozin Propanediol56$58,180
JanuviaSitagliptin Phosphate26$29,453
MounjaroTirzepatide26$27,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,062
Atorvastatin Calcium1,028$10,200
SymbicortBudesonide/Formoterol Fumarate20$6,823
Rosuvastatin Calcium306$5,514
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$4,588
Amlodipine Besylate930$4,391
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$781$221,810215 claims
Boehringer IngelheimJardiance$297$105,687100 claims
Lilly USA, LLCTrulicity, Mounjaro$442$100,88296 claims
Johnson & JohnsonXarelto$370$77,84186 claims
AstraZenecaFarxiga, Symbicort$631$65,00376 claims
PfizerEliquis, Paxlovid$354$61,87787 claims
MerckJanuvia$199$29,45326 claims
GSKTrelegy Ellipta$936$15,06221 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$2,574264 claims
Sanofi-aventis U.S. LLCLantus$123$2,12221 claims
AbbVieSynthroid$719$1,14719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Beachwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →